- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07646587
A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) (Sirius)
10. september 2026 oppdatert av: Windward Bio
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease
This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD).
WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms.
The study will test how doses of WIN378 are handled by the body (pharmacokinetics) and assess the safety of the medicine and markers of COPD inflammation in exhaled breath and blood, lung function and COPD control (pharmacodynamics)
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, tolerability, and pharmacokinetics of WIN378 in adult participants with moderate - severe chronic obstructive pulmonary disease (COPD).
Participants will continue their standard background COPD therapy.
Eligible participants will receive doses of WIN378 or placebo over a 24-week treatment period.
Studietype
Intervensjonell
Registrering (Antatt)
105
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Juliana Hutchinson, MSc
- Telefonnummer: +4161 551 75 75
- E-post: clinical.trial.enquiry@windwardbio.com
Studiesteder
-
-
Buenos Aires
-
Buenos Aires, Buenos Aires, Argentina, C1023AAB
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1028AAP
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1122AAK
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1425BEN
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C1425FVH
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires, Argentina, C142ABP
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Buenos Aires F.D.
-
Buenos Aires, Buenos Aires F.D., Argentina, C1414AIF
- Rekruttering
- WB Contracted Clinical Research Site
-
Buenos Aires, Buenos Aires F.D., Argentina, C1426ABP
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Mendoza Province
-
Buenos Aires, Mendoza Province, Argentina, M5500AXR
- Rekruttering
- WB Contracted Clinical Research Site
-
Mendoza, Mendoza Province, Argentina, M5500CBA
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000KZD
- Rekruttering
- WB Contracted Clinical Research Site
-
Rosario, Santa Fe Province, Argentina, S2013OJN
- Rekruttering
- WB Contracted Clinical Research Site
-
Santa Fe, Santa Fe Province, Argentina, S3000ASF
- Rekruttering
- WB Contracted Clinical Research Site
-
-
-
-
California
-
Los Angeles, California, Forente stater, 93534
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Florida
-
Miami Lakes, Florida, Forente stater, 33014
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Massachusetts
-
North Dartmouth, Massachusetts, Forente stater, 02747
- Rekruttering
- WB Contracted Clinical Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Forente stater, 28277
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Oregon
-
Medford, Oregon, Forente stater, 97504
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Pennsylvania
-
DuBois, Pennsylvania, Forente stater, 15801
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Texas
-
McKinney, Texas, Forente stater, 75069
- Rekruttering
- WB Contracted Clinical Research Site
-
Waxahachie, Texas, Forente stater, 75165
- Rekruttering
- WB Contracted Clinical Research Site
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Adults aged 40 to 80 years
- Post-BD spirometry at screening FEV1/FVC < 0.70 and FEV1 30-80% predicted
- On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months
- Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months
- Elevated eosinophil count
- Weight/BMI within allowed range
Exclusion Criteria:
- Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD)
- Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct
- Clinically significant cardiovascular disease
- Recent respiratory infection or COPD exacerbation
- Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period
- Pregnancy or breastfeeding
- Smoking or diagnosed substance use disorder
- Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: WIN378 Dose 1
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Eksperimentell: WIN378 Dose 2
WIN378 SC injections will be administered
|
WIN378 is a fully human, long-acting monoclonal antibody that targets the ligand of thymic stromal lymphopoietin (TSLP), blocking its activity and thereby reducing airway inflammation and improving COPD control over an extended dosing interval
|
|
Eksperimentell: Placebo
Placebo SC injections will be administered
|
Placebo matching WIN378
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Adverse Events (AEs)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Number of participants with Serious Adverse Events (SAEs)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in systolic blood pressure (mmHg)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in diastolic blood pressure (mmHg)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in pulse rate (beats/minute)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in respiratory rate (breaths/minute)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in oxygen saturation (%)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body weight (kg)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body mass index (kg/m^2)
Tidsramme: Week 0 - Week 36
|
Week 0 - Week 36
|
|
|
Change from baseline in body temperature (°C)
Tidsramme: Week 0- Week 36
|
Week 0- Week 36
|
|
|
Change from baseline in clinical chemistry laboratory assessments
Tidsramme: Week 0 - Week 36
|
Clinical chemistry assessments will include serum chemistry (such as sodium, potassium, urea, creatinine) and liver function parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and bilirubin.
|
Week 0 - Week 36
|
|
Change from baseline in haematology laboratory parameters
Tidsramme: Week 0 - Week 36
|
Haematology assessments will include haemoglobin, white blood cell count, differential white blood cell counts and platelet count
|
Week 0 - Week 36
|
|
Change from baseline in coagulation laboratory parameters
Tidsramme: Week 0 - Week 36
|
Coagulation assessments will include activated partial thromboplastin time, international normalised ratio, prothrombin time and fibrinogen
|
Week 0 - Week 36
|
|
Change from baseline in urinalysis parameters
Tidsramme: Week 0 - Week 36
|
Urinalysis assessments will include protein, pH, blood, glucose and leucocytes
|
Week 0 - Week 36
|
|
Change from baseline in electrocardiogram QT interval
Tidsramme: Week 0 - Week 36
|
Electrocardiogram assessments will include evaluation of QT interval corrected using Fridericia's formula (QTcF)
|
Week 0 - Week 36
|
|
WIN378 Serum concentration (PK)
Tidsramme: Week 0 to week 36
|
Week 0 to week 36
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Change from baseline in Blood Eosinophil Count
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Fractional Exhaled Nitric Oxide (FeNO)
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Change in Pre and Post Bronchodilator Forced Vital Capacity (FVC)
Tidsramme: Week 0 to Week 24
|
Week 0 to Week 24
|
|
Incidence and magnitude of anti-drug antibodies to WIN 378
Tidsramme: Week 0 to Week 36
|
Week 0 to Week 36
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Omar Khwaja, MD, Windward Bio
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
2. juni 2026
Primær fullføring (Antatt)
17. desember 2027
Studiet fullført (Antatt)
7. januar 2028
Datoer for studieregistrering
Først innsendt
2. juni 2026
Først innsendt som oppfylte QC-kriteriene
9. juni 2026
Først lagt ut (Faktiske)
12. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. september 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. september 2026
Sist bekreftet
1. september 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- WB-2102
- U1111-1333-4974 (Annen identifikator: UTN, World Health Organization (WHO))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .